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| INTRODUCTION
There are an estimated 240 million people with chronic hepatitis B virus (HBV) infection globally, and about 650 000 will die due to chronic hepatitis B (CHB) annually. 1 Chronically HBV-infected patients have high risk of developing hepatic decompensation, cirrhosis, and hepatocellular carcinoma (HCC) if they could not receive timely and appropriate treatments. 1, 2 Clinical studies have suggested that antiviral treatments may prevent progression to cirrhosis, and reduce the risk of HCC and liver-related deaths 3 ; however, the current treatment methods failed to eradicate the virus in majority of CHB patients.
Pegylated interferon-α (PEG-IFN-α), which stimulates the immune responses of the host to HBV, is one of the first-line treatment agents recommended by major liver societies treatment guidelines. 2, 4, 5 The advantages of PEG-IFN-α therapy including a finite treatment course, a relatively higher hepatitis B e antigen (HBeAg) seroconversion rate in HBeAg-positive patients, sustained virological response (SVR), and a relatively high hepatitis B surface antigen (HBsAg) seroclearance or seroconversion rate. 6, 7 However, PEG-IFN-α treatment is expensive, inconvenient for clinical application, less well tolerated, and with limited response rate. 2 Therefore, identifying those patients that are response to PEG-IFN-α therapy will guide the clinical treatment choices. Up to date, many clinical studies have reported that ALT, HBsAg, HBeAg, and HBV DNA levels, the host IL28B genotype and HBV genotype were associated with the responses to PEG-IFN-α therapy in CHB patients. 6, [8] [9] [10] [11] [12] [13] Meanwhile, the quantitative serum HBsAg at week 12, the decline of serum HBsAg level as well as HBV DNA level at week 24 were also predictive factors for PEG-IFN-α therapy. 14 However, the sensitivity and specificity of these biomarkers are still limited and novel biomarkers are warranted to guide clinical selection of PEG-IFN-α in CHB patients.
Mac-2-binding protein glycosylation isomer (M2BPGi), a glycobiomarker, was firstly reported by Kuno et al as a novel biomarker in assessing the liver fibrosis severity in chronic hepatitis patients. 15 Subsequently, studies reported that M2BPGi level might be a noninvasive marker for the assessment of liver fibrosis in patients with chronic hepatitis C (CHC), CHB, nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), and primary biliary cirrhosis (PBC). [16] [17] [18] [19] [20] Recently, Nishikawa et al found that pretreatment M2BPGi level might be a useful predictor for HBeAg loss or seroconversion for
HBeAg-positive CHB patients that received the treatment of nucleoside/nucleotide analogs (NUCs). 21 However, the predictive roles of M2BPGi for PEG-IFN-α treatment in CHB patients are still unknown.
Thus, the aim of the current study was to investigate the roles and 
| Clinical and laboratory measurement
The whole blood samples were collected using vacuum blood tubes with coagulant and the serum was aliquoted and stored at −80°C until analysis. The blood samples were taken at baseline S/CO P < 0.001), and week 24 (228.08 S/CO vs 6.36 S/CO, P < 0.001)
were noticed in patients with non-VR groups compared to VR groups ( Figure 1 and Supplementary Table S1 ). HBV DNA at weeks 4, 12, and 24 in the non-VR groups were significantly higher than patients in VR groups ( Figure 1 and Supplementary Table S1 ). No significantly differences were noticed for HBsAg, and ALT (P > 0.05; Supplemen- tary Table S1 ) between the non-VR and VR groups for patients received Peg-IFN-α treatment. (Table 1) .
Compared to SR group, patients in the non-SR group had significantly higher HBeAg and HBV DNA at weeks 12 and 24; however, the difference was not statistically significant at week 4 after the treatment ( Figure 2 and Supplementary Table S1 ). No significantly differences were noticed in M2BPGi, HBsAg, and ALT between the non-SR and SR groups during the treatment (Figure 2 and Supplementary Table S1 ).
| Clinical characteristics factors associated with virological or serological response to Peg-IFN-α treatment
Univariate analysis suggested that baseline HBeAg and M2BPGi levels were significantly associated with VR after 48-week Peg-IFN-α treatment (Table 2 ). HBeAg as well as HBV-DNA levels at weeks 12 and 24 were associated with VR after the 48-week
Peg and cytokine IP-10 levels, 19, 21, 28 which suggested that M2BPGi might be associated with host immune activation. It has been reported that serum M2BPGi can be used to evaluate liver fibrosis caused by a variety of etiology, and it was associated with hepatocellular carcinoma (HCC) risk in chronic HBV or HCV patients. [16] [17] [18] [19] [20] 29, 30 Moreover, M2BPGi is also a novel predictive biomarkers to NUCs as HBsAg, HBV surface antigen; HBeAg, HBV e antigen; ALT, alanine aminotransferase; M2BPGi, Mac-2 binding protein glycosylation isomer. Values expressed as odds ratio (OR) and 95% confidence interval (CI). A P value < 0.05 is labeled as bold.
suggested by a study performed by Nishikawa et al. 21 However ), low HBeAg, high serum ALT levels (>2-5 × ULN) and high hepatic activity score of liver biopsy (at least A2) at baseline are associated with HBeAg seroconversion. 13, 14 HBsAg <1500 IU/mL at week 12 after the treatment was a strong predictor of HBeAg seroconversion, 33 while
HBsAg levels >20 000 IU/mL or show no HBsAg levels decline at 12 weeks are associated with a low chance of HBeAg seroconversion at week 48. 34 Fried et al reported that a HBV DNA decrease to <20 000 IU/mL at week 12 was associated with a 50% chance of anti- We acknowledged that there are several limitations for the current study. First, the study is a retrospective study with a limited sample size. The patients were followed up for a short time and it was not possible to evaluate the sustained responses of the patients after discontinuation of the treatment. Second, the HBV genotype was not determined, which may influence the outcomes for Peg-IFN-α treatment. Previous studies have shown that the HBV genotypes prevalent in Chinese population are mostly genotypes B and C, and genotype B is associated with better responses to interferon therapy
FIGURE 3
The receiver operating characteristics curves of M2BPGi, HBV-DNA, and HBsAg at baseline in predicting antiviral response after 48-week Peg-IFN-α treatment in CHB patients. Left, virological response; right, serological response than genotype C. 6 Thus, the HBV genotypes should be taken into consideration to evaluate the associations between the M2BPGi and clinical responses in future. Third, genetic background that might be associated with the responses to Peg-IFN-α treatment was not determined such as the single nucleotide polymorphisms (SNPs) located within IL28B. However, whether these SNPs affect the response to interferon therapy is still controversial in CHB patients. 39, 40 Thus, further studies with large number of patients are needed to validate the results.
In conclusion, our current study found that baseline serum M2BPGi has predictive value for the clinical responses of HBeAgpositive chronic hepatitis B patients receiving Peg-IFN-α treatment.
More studies with larger sample size are warranted to validate the results and the underlying mechanisms need to be explored. 
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